ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
15 announcements
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.
Orchid Pharma's Q1FY27 revenue grew 15% YoY to INR 304Cr, with EBITDA rising to INR 25Cr. The company is pivoting toward complex, high-value molecules and backward integration.
Management reports a recovery in Q1 FY27 with 15% revenue growth after a difficult FY26, but remains cautious due to industry-wide overcapacity and pricing pressure.
Orchid Pharma reported strong Q1FY27 performance following the strategic amalgamation of Dhanuka Laboratories, transforming into an integrated cephalosporin platform with a significant turnaround in profitability metrics.
Orchid Pharma Ltd reported revenue from operations of ₹368.3 Cr (+3.0% YoY) and net profit of ₹25.8 Cr (-24.1% YoY) for Q4 FY26.
Orchid Pharma Ltd reported revenue from operations of ₹304.2 Cr (+15.6% YoY) and net profit of ₹3.2 Cr for Q1 FY27.
Orchid Pharma reports FY26 standalone revenue of ₹811cr and EBITDA of ₹101cr. Strategy shifts towards platform creation, including the Dhanuka merger and entering the U.S. sterile formulation market.
Orchid Pharma is pivoting from a recovery phase to a higher-margin 'platform creation' model, integrating Dhanuka Laboratories and aggressively targeting the US sterile cephalosporin market.
Orchid Pharma reports FY26 standalone revenue of ₹811 Cr and PAT of ₹45 Cr, focusing on transitioning from a turnaround to an integrated cephalosporin platform with major capex in 7ACA.
Orchid Pharma Ltd reported revenue from operations of ₹237.6 Cr (+0.0% YoY) and net profit of ₹23.8 Cr (+6.7% YoY) for Q4 FY26.